Showing 1–25 of 35 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Singh S, Gumbo T, Alffenaar JW, Boorgula GD, Shankar P, et al.
…nd other drugs was tested to identify alternative treatment regimens for multidrug-resistant tuberculosis (MDR-TB). Methods The following were performed: (1) MIC experiments; (2) static time-kill studies (STKs) with different BLIs; and (3) a hollow fibre model system of TB (HFS-T…
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, et al.
…TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been …
Tushar R. Sahasrabudhe
…tional TB Elimination Programme (NTEP) has fixed 2HREZ/4HRE regimen for all drug-sensitive (DS-TB) cases, comprising of isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z). These potent first-line drugs, i.e., HREZ, are the backbone of DS-TB treatment for last man…
Rivaldo Heru Setiawan
…lobal public health challenge, with multidrug-resistant TB (MDR-TB) contributing substantially to poor outcomes. Conventional regimens span 18–24 months, leading to limited adherence and treatment success. Shorter treatment regimens (STRs), such as the BPaL regimen (bedaquiline, …
Tari Nur Fauziyantini, Umi Yuniarni, Lanny Mulqie
…especially in the case of Multidrug-Resistant Tuberculosis (MDR-TB). This study aims to examine the TB-RO therapy regimen that applies in Indonesia through a descriptive analysis approach. The research process was carried out by searching, selecting and analyzing scientific liter…
Serisha Ramasir, Frasia Oosthuizen, Varsha Bangalee
… of said guidelines. The multi-drug resistant tuberculosis (MDR-TB) guideline has undergone major changes over the past 5 years. These changes included shorter treatment regimens and the introduction of novel drugs. These changes have consequently impacted the management of MDR-T…
Piamlarp Sangsayunh, Thanyanuch Sanchat, Charoen Chuchottaworn, Krisana Cheewakul, Sirijit Rattanawai
…nges associated with the implementing of the groundbreaking BPaL-containing regimen in Thailand. Another aim was to investigate the characteristics and severity of the disease, the presence of abnormal extensive lesions in chest X-Rays and the influence of cavitation on sputum co…
Zarir F Udwadia, Jigneshkumar M. Patel
…ease in the number of cases of TB and multi-drug resistant (MDR-TB) has unravelled decades of progress and reflects the profound impact COVID-19 has had on tuberculosis. Despite this grim news, these are exciting times for doctors treating Drug Resistant TB (DR-TB) and for their …
Mota F, Ruiz-Bedoya C, Tucker E, De Jesus P, Flavahan K, et al.
…anid is used in combination with bedaquiline and linezolid (BPaL regimen) in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, the penetration of pretomanid in privileged sites remain unknown. Antimicrobial pharmacokinetic (PK) parameters are traditionally deri…
Filipa Mota, Camilo A. Ruiz-Bedoya, Elizabeth W. Tucker, Patricia De Jesus, Kelly Flavahan, et al.
…anid is used in combination with bedaquiline and linezolid (BPaL regimen) in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, the penetration of pretomanid in privileged sites remain unknown. Antimicrobial pharmacokinetic (PK) parameters are traditionally deri…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Rajendra Prasad, Harsh Saxena, Nikhil Gupta, Mohammad Tanzeem, Ronal Naorem1
… of DR-TB with or without newer anti-TB drugs. multi-DR-TB (MDR-TB) patients have now choice of two types of regimen, shorter and longer regimens. Shorter regimen for treatment of subset of MDR-TB patients who have not been previously treated with second line drugs and in whom re…
Kavitha Saravu, Madhukar Pai
…ant TB (RR-TB), and 82% of them had multidrug-resistant TB (MDR-TB); 3.5% of new TB cases and 18% of previously treated cases had MDR/RR-TB. A quarter of the DR-TB cases globally were from India.[1] Only about 25% of these estimated MDR-TB or RR-TB were diagnosed and notified. Th…
Oki Nugraha Putra, Telly Purnamasari
…red either a shorter (9 months) or individualized treatment regimen (18 months). However, long treatment duration with various adverse events affects patient compliance. Therefore, a short treatment with less medication is urgently required. In 2022, the WHO announced an alternat…
Carlos Acuña-Villaorduña, Karen R. Jacobson, C. Robert Horsburgh, Martin Canning, Pranay Sinha
Initial experience with BPaL-based regimens to treat multidrug-resistant TB Dear Editor, We read with interest the recent article on the latest WHO guidelines on drug-resistant TB. 1 The recommendation to implement all-oral regimens containing bedaquiline, pretomanid and linezoli…
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…XDR-TB are highly DR-TB with a lower success treatment than MDR-TB. Therapy for high DR-TB with fewer drugs and shorter treatment is required to increase the success of treatment. We comprehensively reviewed the risk factors for unfavorable outcomes (death, treatment failure, and…
Girase R, Ahmad I, Patel H
…against M. tuberculosis and is a crucial constituent of the BPaL regimen (Bedaquiline, Pretomanid, and Linezolid), which was authorized by the FDA in 2019 for the treatment of XDR-TB or MDR-TB. Despite its unique mechanism of action, Linezolid carries a considerable risk of toxic…
George Ikpe, Shadrach Dimang, Ufuoma Aduh, Peter Idowu Omoniyi, Ugochukwu Chukwulobelu, et al.
…CTION:** the treatment of multidrug-resistant tuberculosis (MDR-TB) has been challenging, often associated with life-threatening adverse events and poor treatment outcomes. The recent World Health Organization (WHO) recommendation of the BPaLM regimen, consisting of bedaquiline, …
Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, et al.
…ew treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in t…
Bruning-Barry R, Ambroso JL, Dillberger J, Yang TJ
…in more than 10 countries as part of a three-drug, all oral regimen, consisting of bedaquiline, pretomanid, and linezolid (BPaL) for 6-months treatment of adults with pulmonary extensively drug-resistant tuberculosis (XDR-TB) or with complicated forms of multidrug-resistant tuber…
Christoph Lange, Yousra Kherabi, Lorenzo Guglielmetti, Raquel Duarte, Gunar Günther
…G. et al. “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe”, published in this journal ( 1 Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Trials group. Availability of drugs and…
Suman Saurabh, Pankaj Bhardwaj
… the recommendation of a shorter all-oral bedaquiline-based regimen for 9–12 months for multidrug or rifampicin-resistant (MDR/RR) tuberculosis, which replaces the current shorter regimen with injectables. The need for a shorter all-oral regimen had been long-felt by experts.[2] …
Michael Ladna
… anastomosis. Case Description/Methods: A man in his 40s on BPAL-M regimen for MDR pulmonary TB presented to Emergency Department with abdominal pain, vomiting, and cessation of bowel movements. Computed tomography abdomen/pelvis showed small bowel obstruction with a terminal ile…
Galo A. Goig, Chloé Loiseau, Nino Maghradze, Kakha Mchedlishvili, Teona Avaliani, et al.
Abstract Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB are threatening global TB control. The World Health Organization has recently endorsed new regimens for the treatment of MDR-TB that rely on the new and repurposed drugs bedaquiline, pretom…